Drug
Sep 363856
Sep 363856: highest development phase Phase 3, developed by Otsuka, Sumitomo Pharma. 9 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Otsuka, Sumitomo Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| SEP-363856 NCT07759128 | Phase 3 | Generalized Anxiety Disorder |
| SEP-363856 NCT07786454 | Phase 3 | Generalized Anxiety Disorder |
| SEP-363856 NCT07767903 | Phase 3 | Generalized Anxiety Disorder |
| SEP-363856 NCT04109950 | Phase 3 | Schizophrenia |
| SEP-363856 50 mg NCT04825860 | Phase 2/3 | Schizophrenia |
| SEP-363856 NCT02970929 | Phase 2 | Schizophrenia |
| SEP-363856 NCT02969382 | Phase 2 | Schizophrenia |
| SEP-363856 NCT05402111 | Phase 1 | Schizophrenia |
| SEP-363856 NCT04325737 | Phase 1 | Schizophrenia |
Latest
No recent events.
Follow Sep 363856 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.